<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04195568</url>
  </required_header>
  <id_info>
    <org_study_id>CDM10001444</org_study_id>
    <nct_id>NCT04195568</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety and Effectiveness of Stryker Surpass Evolve™ Flow Diverter System</brief_title>
  <acronym>EVOLVE</acronym>
  <official_title>EndoVascular Treatment Of Wide-Neck Aneurysms, an EvaLuation of Safety and EffectiVeness of Stryker Surpass Evolve™ Flow Diverter System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stryker Neurovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stryker Neurovascular</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and effectiveness of the&#xD;
      Surpass™ Evolve Flow Diverter System in the treatment of unruptured, wide-neck intracranial&#xD;
      aneurysms measuring ≤ 12 mm and located on the ICA or its branches&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Surpass Evolve Flow Diverter System is indicated for the endovascular treatment of adults&#xD;
      (age 18 or above) with unruptured saccular wide-neck or fusiform intracranial aneurysms ≤ 12&#xD;
      mm for treatment in vessel diameters between 1.75-5.0mm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 7, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 28, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Effectiveness Endpoint</measure>
    <time_frame>12 months (± 3 months) post procedure</time_frame>
    <description>The primary effectiveness endpoint of this study is a composite of 100% occlusion (Raymond 1, complete occlusion) of the target aneurysm without significant parent artery stenosis (&gt;50% stenosis), per independent core lab assessment of digital subtraction angiography (DSA) images acquired at 12 months (± 3 months) post-procedure, and with no target aneurysm retreatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Safety Endpoint</measure>
    <time_frame>12 Months (± 3 months) post procedure</time_frame>
    <description>The primary safety endpoint of this study is neurologic death, or disabling stroke at 12 months as adjudicated by an independent Clinical Events Committee (CEC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Safety Endpoints</measure>
    <time_frame>3 Year Follow-Up</time_frame>
    <description>The secondary safety endpoints will be evaluated throughout the study, and are as follows:&#xD;
Neurological death or major ipsilateral stroke as adjudicated by an independent Clinical Events Committee.&#xD;
Stroke in the treated vascular territory as adjudicated by a Clinical Events Committee</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">235</enrollment>
  <condition>Aneurysm, Intracranial</condition>
  <arm_group>
    <arm_group_label>Surpass Evolve Flow Diverter System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a prospective single arm study in which all subjects who present for flow diverter implantation, provide informed consent, and meet inclusion/exclusion criteria may receive treatment (Surpass Evolve Flow Diverter).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Surpass Evolve Flow Diverter System</intervention_name>
    <description>The Surpass Evolve Flow Diverter System is indicated for the endovascular treatment of adults (age 18 or above) with unruptured saccular wide-neck or fusiform intracranial aneurysms ≤12 mm.</description>
    <arm_group_label>Surpass Evolve Flow Diverter System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age is ≥ 18 and ≤ 80 years&#xD;
&#xD;
          2. Has a single unruptured target intracranial aneurysm (IA) with the following&#xD;
             characteristics:&#xD;
&#xD;
               1. Is located on the internal carotid artery (ICA) or its branches.&#xD;
&#xD;
               2. Has a neck ≥ 4 mm, dome to neck ratio ≤ 2.0, or no discernible neck&#xD;
&#xD;
               3. Aneurysm size is ≤ 12 mm (saccular or fusiform configuration)&#xD;
&#xD;
          3. Has a parent vessel diameter ≥ 1.75 mm and ≤ 5.0 mm at both the proximal and distal&#xD;
             segments where the implant will be placed&#xD;
&#xD;
          4. Has multiple increased risk factors for intracranial (IA) aneurysm rupture, including&#xD;
             but not limited to, aneurysm morphology, smoking, hypertension, diabetes, age, prior&#xD;
             and/or family history of rupture, and/or history of subarachnoid hemorrhage that may&#xD;
             result in a benefit risk profile of endovascular treatment that outweighs the risks of&#xD;
             intracranial aneurysm rupture during the subject's expected lifetime if left&#xD;
             untreated.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has an extradural target aneurysm&#xD;
&#xD;
          2. Has a target aneurysm in the posterior circulation&#xD;
&#xD;
          3. Perforator or branch vessel, inclusive of the posterior communicating artery, arises&#xD;
             from the target aneurysm body or neck (branches or arteries must arise or connect from&#xD;
             the parent vessel separate from the aneurysm or neck to not be excluded from study)&#xD;
&#xD;
          4. Has a true bifurcation aneurysm, defined as an aneurysm (saccular or non-saccular)&#xD;
             located at a point of vessel bifurcation&#xD;
&#xD;
          5. Target aneurysm is unsuitable for flow diverter treatment&#xD;
&#xD;
          6. Has vessel characteristics, such as severe tortuosity, stenosis, or morphology that&#xD;
             would preclude safe endovascular access to the target aneurysm necessary for treatment&#xD;
             with the study device (e.g., which may be evidenced by excessive resistance felt&#xD;
             during the procedure); or, presence of intracranial atherosclerotic disease or&#xD;
             stenosis&#xD;
&#xD;
          7. Received previous treatment of the target aneurysm or parent artery where it would&#xD;
             interfere with the placement or proper apposition of the device&#xD;
&#xD;
          8. Has a medical contraindication to study or procedure related antiplatelet medications&#xD;
             (aspirin, clopidogrel/Plavix, ticagrelor, and heparin), local or general anesthesia,&#xD;
             or lifethreatening allergy to contrast dye&#xD;
&#xD;
          9. Has a known severe allergy to nickel, chromium cobalt, tungsten or platinum.&#xD;
&#xD;
         10. Modified Rankin Score (mRS) assessment is ≥ 3 at preprocedure exam&#xD;
&#xD;
         11. Presence of unstable neurological deficit (i.e., worsening of clinical condition in&#xD;
             the last 30 days)&#xD;
&#xD;
         12. Subarachnoid hemorrhage occurred within 30 days prior to enrollment&#xD;
&#xD;
         13. Major surgery (including previous intracranial implant) occurred within previous 30&#xD;
             days or is planned in the next 120 days after enrollment date&#xD;
&#xD;
         14. Has more than one IA that requires treatment within 12 months&#xD;
&#xD;
         15. Received previous intracranial implant associated with the symptomatic or vascular&#xD;
             distribution within the past 12 weeks prior to treatment date&#xD;
&#xD;
         16. Chronic anticoagulation therapy is ongoing or known coagulopathy exists&#xD;
&#xD;
         17. Has other known serious concurrent medical conditions such as heart disease (including&#xD;
             atrial fibrillation, pacemaker, recent myocardial infarction [&lt; 12 weeks], symptomatic&#xD;
             congestive heart failure, or carotid stenosis), kidney failure [&gt;2.0mg/dl serum&#xD;
             creatinine], pulmonary disease, uncontrolled diabetes, progressive neurologic&#xD;
             disorders, terminal cancer, vasculitis, high risk of ischemic stroke or recent stroke&#xD;
&#xD;
         18. Has acute life-threatening illness other than the neurological disease (e.g., acute&#xD;
             kidney or heart failure) to be treated in this trial&#xD;
&#xD;
         19. Life expectancy is less than 5 years due to other illness or condition (in addition to&#xD;
             an intracranial aneurysm)&#xD;
&#xD;
         20. Unable to complete study follow up due to dementia or psychiatric problem, substance&#xD;
             abuse, or history of noncompliance with medical advice&#xD;
&#xD;
         21. Pregnancy at time of enrollment&#xD;
&#xD;
         22. Presence of intracranial mass (tumor, except meningioma, abscess, or other infection),&#xD;
             non-treated arteriovenous malformation (AVM) in the territory of the target aneurysm&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam S Arthur, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Semmes Murphy Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vitor M Pereira, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chris Butler</last_name>
    <phone>470 419 0111</phone>
    <email>chris.butler@stryker.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Scott Courts</last_name>
    <phone>925 519 7483</phone>
    <email>scott.courts@stryker.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>DIGNITY HEALTH/ Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret M.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachael T.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lyerly Baptist, Inc./Baptist Medical Center - Jacksonville/Lyerly Neurosurgery</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy E.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advocate Lutheran General Hospital</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gina L.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren S.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nora F.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heena O.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baptist Healthcare System, Inc./Baptist Health</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mandy C.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah C.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah G.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jared B.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICAHN School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serina D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stony Brook</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marlene B.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Bynam</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73019</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blair A.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Semmes Murphey Clinic/ University of Tennessee Health Sciences Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica W.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte G.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>NSW 2170</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan M.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gold Coast Hospital &amp; Health Service/ Gold Coast University Hospital</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl R.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Health Network/ Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex K.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 4, 2019</study_first_submitted>
  <study_first_submitted_qc>December 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Aneurysm</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium Carbonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

